Tirzepatide Reduces Both Cardiovascular and Lower Extremity Complications in Atherosclerosis Patients | Research

The takeaway

Tirzepatide was associated with reduced major adverse cardiovascular and limb events in patients with atherosclerosis, demonstrating comprehensive vascular protection in a large retrospective cohort.

Heart AND legs protected
Tirzepatide reduced both cardiovascular and lower-extremity events — comprehensive vascular protection from coronary to peripheral arteries

What the researchers found

Tirzepatide use associated with reduced both MACE (cardiovascular events) and MALE (limb events) in patients with atherosclerosis, demonstrating pan-vascular protective effects.

Why it matters

Atherosclerosis affects the whole arterial system. A drug that protects both the heart AND the legs provides comprehensive vascular care.

How the study worked

Retrospective TriNetX cohort study evaluating tirzepatide vs controls for cardiovascular and lower-extremity atherosclerotic outcomes.

What this study cannot tell us

Retrospective. Cannot determine if GIP agonism adds vascular benefit vs GLP-1 alone.

How to read the evidence

Retrospective TriNetX cohort. Consistent pan-vascular signal.

When this study was published

Published in 2025.

The bigger picture

Tirzepatide's dual GIP/GLP-1 mechanism may provide vascular protection that extends beyond what GLP-1-only drugs achieve.

Questions still open

Does tirzepatide protect peripheral vessels more than semaglutide?
Should tirzepatide be preferred for PAD patients?
What mechanism explains limb-specific protection?

Common questions

Does tirzepatide protect blood vessels everywhere?

This study found it reduces both heart events and leg circulation problems — suggesting it protects arteries throughout the body, not just the heart.

Is tirzepatide better than other GLP-1 drugs for blood vessels?

Tirzepatide's dual GIP/GLP-1 mechanism may provide additional vascular benefits. Head-to-head comparisons are needed to confirm.

Read the original research

Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin.

Diabetes research and clinical practice, 231, 113072

View on PubMed ↗Publisher’s paper ↗

Citation

Iwasaki, Yoshihiro; Shimada, Takenobu; Kishimori, Takefumi; Kato, Takao; Koike, Jumpei; Matsumoto, Takehiro; Yagi, Takafumi; Okada, Masaharu. (2026). Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin.. Diabetes research and clinical practice, 231, 113072. https://doi.org/10.1016/j.diabres.2025.113072